Faeth Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
FTH$12.92+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(206,641) | $(16,368) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 25,903 | 979 |
| Depreciation and amortization | 71 | 92 |
| Accretion on marketable securities | (2,470) | (584) |
| Non-cash lease expense | 1,168 | 1,136 |
| Amortization of financing lease right-of-use assets | 1 | 13 |
| Acquired in-process research and development from the acquisition of Faeth Therapeutics | 132,957 | — |
| Loss on asset disposal | 30 | 21 |
| Change in fair value of warrant liabilities | 52 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | 10,306 | (23) |
| Other assets | (1,539) | (98) |
| Accounts payable and accrued liabilities | 1,304 | 156 |
| Compensation and employee benefits | 733 | (726) |
| Operating lease liabilities | (1,283) | (1,187) |
| Net cash used in operating activities | (39,408) | (16,589) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (9) | (16) |
| Purchases of short-term investments | (235,382) | (18,633) |
| Maturities of short-term investments | 89,600 | 36,090 |
| Proceeds from sale of property and equipment | — | 250 |
| Net cash assumed in the acquisition of Faeth Therapeutics | 6,464 | — |
| Net cash (used in) provided by investing activities | (139,327) | 17,691 |
| Cash flows from financing activities | ||
| Principal payments for financing leases | (80) | (677) |
| Proceeds from the sale of financing lease assets | — | 142 |
| Proceeds from issuance of Series B redeemable convertible preferred stock | 200,000 | — |
| Issuance costs from the private placement issuance of Series B redeemable convertible preferred stock | (16,908) | — |
| Payment of employee restricted stock tax withholdings | — | (3) |
| Employee stock purchase plan proceeds | — | 5 |
| Cash in lieu of fractional shares for reverse stock split | — | (1) |
| Exercise of options into common stock | 1,235 | — |
| Net cash provided by (used in) financing activities | 184,247 | (534) |
| Net increase in cash and cash equivalents | 5,512 | 568 |
| Cash and cash equivalents at beginning of period | 8,668 | 9,994 |
| Cash and cash equivalents at the end of period | $14,180 | $10,562 |
| Supplemental disclosure of noncash financing information: | ||
| Fair value of Series B redeemable convertible preferred stock issued for the acquisition of Faeth Therapeutics | $145,384 | $— |
| Net assets acquired in the acquisition of Faeth Therapeutics | $12,879 | $— |
| Conversion of Series B Preferred Stock to Common Stock | $321,709 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.